glp-1 vs glp-1/gip The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology xmlinkhub
Description
Its not a one time appointment
The SURMOUNT trials ran for 72 weeks with similar weight regain patterns after discontinuation
It is about understanding that midlife is not a neutral backdrop for medication use
And Im excited to watch it all.
Novo Nordisk CEO Mike Doustdar thinks that in the coming years obesity will look like mental health once did, where people labeled it as one condition
